Trial · NCT02285088
A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease
NCT02285088, Phase 1, Completed, Global Blood Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease. Trials, record NCT02285088. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02285088
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease
- NCT number
- NCT02285088
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 133 participants, actual
- Lead sponsor
- Global Blood Therapeutics
- Conditions
- Healthy Subjects, Sickle Cell Disease
- Interventions
- GBT440, Placebo
- First posted
- 2014-11-06
- Last updated
- 2018-02-15
- Other registries' IDs
- eudract:2014-003555-62
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety, as assessed by frequency and severity of adverse events (AEs), and changes in vital signs, 12-lead electrocardiograms (ECGs), and laboratory assessments as compared to baseline | 30 - 118 days | |
| Secondary | Blood and plasma area under the concentration time curve (AUC) of GBT440 | 30 - 118 days | |
| Secondary | Blood and plasma maximum concentration (Cmax) of GBT440 | 30 - 118 days | |
| Secondary | Blood and plasma time to maximum concentration (Tmax) of GBT440 | 30 - 118 days | |
| Secondary | Percentage of hemoglobin occupied or modified by GBT440 | 30 days | |
| Secondary | Change from baseline in heart rate and pulse oximetry following exercise testing in healthy volunteers | 30 days | |
| Other | Percentage of sickled cells under ex vivo conditions | 30 - 90 days | |
| Other | Effect of GBT440 on hemolysis as measured by LDH, direct bilirubin, hemoglobin, and reticulocyte count | 30 - 118 days | |
| Other | Change from baseline in pain as measured by visual analog scale | 30 days | |
| Other | Change from baseline in fatigue as measured by questionnaire | 30 - 118 days |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30655275 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02285088
GET https://conductscience.org/api/trials/v1/NCT02285088/registered